Sanofi

Sanofi-a Ventis Deutschland Gmbh

Mcmaster University

Thorsten Sadowski

Klaus Wirth

Christian Buning

Herman Schreuder

Sven Ruf

Georg Horstick

Josef Pernerstorfer

Hartmut Strobel

Christopher Kallus

Hermut Wehlan

Thomas Olpp

Hertzel Gerstein

Gregory Steinberg

Sibylle Hess

Guillaume Pare

Bodo Scheiper

The present invention relates to metformin for use in treating a patient, wherein the patient exhibits an increased level of GDF15 in response to metformin treatment; to methods of identifying a patient who will benefit or who will not benefit from metformin treatment; methods of treating a patient at risk of developing or suffering from a disease or disorder comprising administering therapeutically effective amount of metformin; methods of adapting the dosage of metformin; the usage of GDF15 as biomarker for identifying a patient who will benefit or who will not benefit from metformin treatment, kits for use in identifying a patient who will benefit from metformin treatment and the use of the kits, as well as methods of treating a patient or who will not benefit from metformin treatment.

Growth differentiation factor 15 as biomarker for metformin

The present invention relates to compounds of the formula I, wherein Ht, G, R, R, R, Rand Rhave the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals

The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Biaryl-propionic acid derivatives and their use as pharmaceuticals

The present invention relates to compounds of the formulae Ia and Ib, wherein G, R, R, R, Rand Rhave the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formulae Ia and Ib, their use and pharmaceutical compositions comprising them.

Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals

The present invention relates to compounds of the formula I, wherein A, D, E, L, G, R, R, R, Rand Rhave the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals

The present invention relates to compounds of the formula I, wherein A, D, E, G, R, R, R, R, Rand Rhave the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals

The present invention relates to compounds of the formula I, wherein A, D, E, G, R, R, R, Rand Rhave the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them. 

Growing community of inventors

Frankfurt am Main, Germany

Thorsten Sadowski